Sana Preclinical Data: CAR T Cells Evade Immune Rejection, Produce Durable Anti-Tumor Responses

 Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic preclinical model in vivo, including following tumor cell reinjection

Findings suggest that hypoimmune-modified allogeneic CAR T cell therapeutics might overcome limitations associated with poor cell persistence of allogeneic CAR T cells

Initial clinical data from SC291, a hypoimmune-modified CD19-directed allogeneic CAR T therapy, in patients with B-cell malignancies expected later this year

IND submission expected this year for a second hypoimmune-modified CAR T, SC262, a hypoimmune-modified CD22-directed allogeneic CAR T therapy, in patients who failed CD19 CAR T cell therapy

Hypoimmune data consistent with Science Translational Medicine findings published earlier this week with hypoimmune pancreatic islet cells in preclinical type 1 diabetes models

https://finance.yahoo.com/news/sana-biotechnology-announces-preclinical-data-130000735.html